Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia

NCT06516679 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Lymphoid

Interventions

DRUG: Consolidation #4(without daunorubicin)
DRUG: Consolidation #4(with daunorubicin)
DRUG: Allogeneic hematopoietic stem cell transplantation after Consolidation #4(with daunorubicin)

Sponsor

Yonsei University